nach oben

Drug Safety

Erschienen in:

01.02.2005 | Review Article

The Safety of Newer Antidepressants in Pregnancy and Breastfeeding

verfasst von: Dr Salvatore Gentile

Erschienen in: Drug Safety | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

The pregnancy and postpartum periods are considered to be relatively high risk times for depressive episodes in women, particularly for those with pre-existing psychiatric illnesses. Therefore, it may be necessary to start or continue the pharmacological treatment of depression during these two timeframes. Hence, the aim of this review is to examine the effects on the fetus and infant of exposure, through the placenta and maternal milk, to the following drugs: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram, mirtazapine, venlafaxine, reboxetine and bupropion.

The teratogenic risks, perinatal toxicity and effects on the neurobehavioural development of newborns associated with exposure through the placenta or maternal milk to these medications need to be carefully assessed before starting psychopharmacological treatment in pregnant or lactating women. In spite of the limitations of some of the studies reviewed, the older selective serotonin-reuptake inhibitors (SSRIs) [as we await further data regarding escitalopram] and venlafaxine seem to be devoid of teratogenic risks. By contrast, the data concerning possible consequences related to exposure to SSRIs via the placenta and breastmilk on neonatal adaptation and long-term neurocognitive infant’s development are still controversial. Nevertheless, a number of reports have shown that an association between placental exposure to SSRIs and adverse but self-limiting effects on neonatal adaptation may exist. In addition, the information on both teratogenic and functional teratogenic risks associated with exposure to bupropion, mirtazapine and reboxetine is incomplete or absent; at present, these compounds should not be used as first-line agents in the pharmacological treatment of depression in pregnancy and breastfeeding.

Untreated depression is not without its own risks since mothers affected by depression have a negative impact on the emotional development of their children and major depression, especially when complicated by a delusional component, may lead to the mother attempting suicide and infanticide. Consequently, clinicians need to help mothers weigh the risks of prenatal exposure to drugs for their babies against the potential risks of untreated depression and abrupt discontinuation of pharmacological treatment. Given these situations, we suggest that choosing to administer psychopharmacological treatment in pregnant or breastfeeding women with depression will result primarily from a careful evaluation of their psychopathological condition; currently, the degree of severity of maternal disease appears to represent the most relevant parameter to take this clinical decision.

Nur mit Berechtigung zugänglich

Sundstrom IM, Bixo M, Bjorn I, et al. Prevalence of psychiatric disorders in gynaecologic outpatients. Am J Obstet Gynecol 2001; 184(2): 8–13PubMedCrossRef

Bixo M, Sundstrom-Poromaa I, Bjorn I, et al. Patients with psychiatric disorders in gynaecologic practice. Am J Obstet Gynecol 2001; 185(2): 396–402PubMedCrossRef

Andersson L, Sundstrom-Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 2003; 189(1): 148–54PubMedCrossRef

Halbreich U. Prevalence of mood symptoms and depression during pregnancy: implications for clinical practice and research. CNS Spectr 2004; 9(3): 177–84PubMed

Glotlib I, Whiffen V, Mount J, et al. Prevalence rates and demographic characteristic in pregnancy and postpartum. J Consult Clin Psychol 1989; 57: 269–74CrossRef

Newport DJ, Hostetter A, Arnold A, et al. The treatment of postpartum depression: minimizing infant exposure. J Clin Psychiatry 2002; 63Suppl. 7: 31–44PubMed

Gold LH. Postpartum disorders in primary care: diagnosis and treatment. Prim Care 2002 Mar; 29(1): 27–41PubMedCrossRef

Weimberg MK, Tronick EL. Maternal depression and infant maladjustment: a failure of mutual regulation. In: Nospitz JD, editor. Handbook of child and adolescent psychiatry. New York: John Wiley & Sons, 1997: 122–27

Weimberg MK, Tronick EL. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59Suppl. 2: 53–61

10.

Kornstein SG. The evaluation and management of depression in women across the life span. J Clin Psychiatry 2001; 62Suppl. 24: 11–7PubMed

11.

Brown CS. Depression and anxiety disorders. Obstet Gynecol Clin North Am 2001; 28(2): 241–68PubMedCrossRef

12.

Elia J, Katz IR, Simpson GM. Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 1987; 23: 531–86PubMed

13.

Elia J, Simpson GM. Antidepressant medications during pregnancy and lactation: fetal teratogenic and toxic effects. In: Amsterdam JD, editor. Pharmacotherapy of depression: application for the outpatient practitioner. New York: Marcel Dekker, 1990: 337–79

14.

Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335(14): 1010–5PubMedCrossRef

15.

Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy. Psychol Med 2000; 30(1): 89–94PubMedCrossRef

16.

Pastusak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269(17): 2246–8CrossRef

17.

Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48(10): 996–1000PubMedCrossRef

18.

Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713–8PubMedCrossRef

19.

Diav-Citrin O, Shechtman S, Weinbaum D, et al. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled study cohort [abstract]. Teratology 2002; 65(6): 298

20.

Sinclair J, Birtwistle J, Baldwin D. The Tolerability of Venlafaxine. Rev Comptemp Pharmacother 1998; 9: 333–44

21.

Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998; 279: 609–10PubMedCrossRef

22.

McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10(4): 285–94PubMedCrossRef

23.

Chambers CD, Dick LM, Felix RJ, et al. Pregnancy outcomes in women who use sertraline [abstract]. Teratology 1999; 59(6): 376

24.

Ericson A, Kallen B, Wilholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55(7): 503–8PubMedCrossRef

25.

Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26(1): 44–8PubMed

26.

Vedernikov Y, Bolanos S, Bytautiene E, et al. Effects of fluoxetine on contractile activity of pregnant rat uterine rings. Am J Obstet Gynecol 2000; 182(2): 296–9PubMedCrossRef

27.

Wisner KL, Gelemberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282(13): 1264–9PubMedCrossRef

28.

Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104(5): 1098–102CrossRef

29.

Campino GA. Cardiac arrhythmia in a newborn associated with fluoxetine use during pregnancy [letter]. Ann Pharmacother 2002; 36(3): 533–4CrossRef

30.

McAnally LE, Threlked KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26: 1090–1PubMed

31.

Gram LF. Fluoxetine. N Eng J Med 1994; 331: 1354–60CrossRef

32.

Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993; 92: 721–2PubMed

33.

Nordeng H, Lindemann R, Perminov KV, et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90(3): 288–91PubMedCrossRef

34.

Oberlander TF, Misri S, Fitzgerald CE, et al. Is polypharmacy associated with transient neonatal symptoms following prenatal psychotropic medication exposure? [abstract]. Pediatr Res 2003; 53(4 Pt 2): 426A

35.

Pitfield SF, Oberlander TF, Fitzgerald CE, et al. Prolonged prenatal psychotropic medication exposure reduces T-helper (CD4+) cells in neonates at birth [abstract]. Pediatr Res 2000; 47(4 Pt 2): 76A

36.

Oberlander TF, Grunau RE, Fitzgerald CE, et al. Prenatal psychotropic medication exposure alters acute neonatal pain response. Pediatr Res 2002; 51: 443–53PubMedCrossRef

37.

Rampono J, Proud S, Hackett LP, et al. A pilot study of newer antidepressant concentration in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol, 2004; 7(3): 329–4PubMedCrossRef

38.

Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Women Ment Health, 2004; 7(3): 193–200CrossRef

39.

Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–62PubMedCrossRef

40.

Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159(11): 1889–95PubMedCrossRef

41.

Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73(4): 330–7PubMedCrossRef

42.

Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite in human breast milk. Pediatr Res 1994; 35(1A): 443–5

43.

Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Clin Pharmacol 1999; 48(4): 521–7

44.

Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996; 36(1): 42–7PubMed

45.

Yoshida K, Smith B, Craggs M, et al. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1997; 172: 175–9CrossRef

46.

Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999; 104(1): e11PubMedCrossRef

47.

Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001; 50(10): 775–82PubMedCrossRef

48.

Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32(6): 1253–5PubMedCrossRef

49.

Hale TW, Shurm S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr 2001; 40: 681–4CrossRef

50.

Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104(5): e61PubMedCrossRef

51.

Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry, 2004; 65(9): 1228–34PubMedCrossRef

52.

Kristensen JH, Hackett LP, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002; 18(2): 139–43PubMedCrossRef

53.

Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk [letter]. Br J Psychiatry 1991; 31: 209

54.

Yoshida K, Smith B, Craggs M, et al. Fluvoxamine in breast milk and infant development. Br J Clin Pharmacol 1997; 44: 210–1PubMed

55.

Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–6PubMedCrossRef

56.

Misri S, Kim J, Riggs KW, et al. Paroxetine levels in postpartum depressed women, breast milk and infant serum. J Clin Psychiatry 2000; 61(11): 828–32PubMedCrossRef

57.

Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999; 48(2): 142–7PubMedCrossRef

58.

Ohman R, Hagg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60(8): 519–23PubMedCrossRef

59.

Santos RP, Pergolizzi JJ. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft®). J Perinatol 2004; 24(6): 392–4PubMedCrossRef

60.

Dodd S, Stocki A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000; 15(4): 261–4CrossRef

61.

Mammen PK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58(3): 100–3PubMedCrossRef

62.

Stowe ZN, Hostetter AL, Owens MJ, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003; 64(1): 73–80PubMedCrossRef

63.

Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998; 45(5): 453–7PubMedCrossRef

64.

Wisner KL, Perel JM, Blumer J. Serum sertraline and Ndesmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155(5): 690–2PubMed

65.

Zeskind PS, Stephens LE. Association of maternal-SSRI use during pregnancy and disrupted neonatal sleep organization [abstract]. Pediatr Res 2003; 53(4 Pt 2): 71A

66.

Rampono J, Kristensen JH, Hackett LP, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol 2000; 50(3): 263–8PubMedCrossRef

67.

Spigset O, Carieborg L, Ohman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997; 44(3): 295–8PubMedCrossRef

68.

Piontek CM, Wisner KL, Perel JM, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001; 62(2): 111–3PubMedCrossRef

69.

Unfred CL, Chambers CD, Felix R, Kao K, Dick L, Alvarado S, et al. Birth outcomes among pregnant women taking paroxetine (Paxil®: update presented at the Organization of Teratology Service, 14th Annual Conference; 2001 Jun, Teratology, 63(6)

70.

Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156(11): 1129–32PubMedCrossRef

71.

Gerola O, Fiocchi S, Rondini G. Antidepressant therapy in pregnancy: a review from the literature and report of a suspected paroxetine withdrawal syndrome in a newborn. Riv Ital Pediatr 1999; 25(1): 216–8

72.

Morag I, Batash D, Keidar R, et al. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol 2004; 42(1): 97–100PubMedCrossRef

73.

Salvia-Roiges MD, Garcia L, Gonce-Mellegren A, et al. Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine. Rev Neurol 2003; 36(8): 724–6PubMed

74.

Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit, 2004; 26(6): 685–7PubMedCrossRef

75.

Morison SJ, Grunau RE, Oberlander TF, et al. Infant social behavior and development in the first year of life following prolonged prenatal psychotropic medication exposure. Pediatr Res 2001; 49(4 Pt 2): 28A

76.

Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 175(2): 185–9CrossRef

77.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Press, 1994

78.

Merlob P, Stahl B, Sulkes J. Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel. Eur J Pediatr, 2004; 163(3): 135–9PubMedCrossRef

79.

Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188(3): 812–5PubMedCrossRef

80.

Altshuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56(6): 243–5PubMed

81.

Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethilsertraline in human breast milk and nursing infants. Am J Psychiatry 1997; 154(9): 1255–60PubMed

82.

Epperson R, Czarkowski KA, Ward-O Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001; 158(10): 1631–7PubMedCrossRef

83.

Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotoninergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60(7): 720–6PubMedCrossRef

84.

Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72(2): 184–91PubMedCrossRef

85.

Jensen PN, Olesen OV, Bertelsen A, et al. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 19(2): 236–9PubMedCrossRef

86.

Lee A, Woo J, Ito S. Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol 2004; 190(1): 218–21PubMedCrossRef

87.

Shmidt K, Olesen OV, Jensen PN. Citalopram and breastfeeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47(2): 164–5CrossRef

88.

Escitalopram: Drugdex Drug Evaluations. Original publication: 12/2001; most recent revision: 03/2003: 1-27

89.

Simhandl C, Zhoglami A, Pinder R. Pregnancy during use of mirtazapine. 11th European Congress of Psychoneuropharmacology; 1998; Paris, France. Abstract P.1.038

90.

Kesim M, Yaris F, Kadioglu M, et al. Mirtazapine use in two pregnant women: is it safe? [letter]. Teratology 2002; 66: 204PubMedCrossRef

91.

Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10Suppl. 4: 37–45PubMedCrossRef

92.

Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term of depression: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13(2): 63–73PubMedCrossRef

93.

Guelfi JD, Annsseau M, Timmermann L, et al. Mirtazapine versus venlafaxine in hospitalised severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21(4): 425–31PubMedCrossRef

94.

Saks BR. Treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases.Arch Women Mental Health 2001; 3(4): 165–70CrossRef

95.

Rodhe A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003; 268(3): 219–21CrossRef

96.

Rodhe A, Almut D, Cristoph D. Intravenous mirtazapine for treatment resistant hyperemesis gravidarum. Poster presented at 2nd World Congress of Mental Health, Washington D.C., 2004 Mar 17-20; p 075

97.

Yaris F, Kadioglu M, Kesim M, et al. Newer antidepressants in pregnancy: a prospective outcome of a case series. Reprod Toxicol, 2004; 19(2): 235–8PubMedCrossRef

98.

Yaris F, Yaris E, Kadiouglu M, et al. Use of polypharmacotherapy in pregnancy: a prospective outcome in a case. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(3): 603–5PubMedCrossRef

99.

Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams & Wilkins, 1998

100.

Aichhorn W, Whitworth AB, Weiss U, et al. Mirtazapine and breast-feeding letter. Am J Psychiatry, 2004; 161(12): 2325PubMedCrossRef

101.

Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728–30PubMedCrossRef

102.

de Moor RA, Mourad L, ter Haar J, et al. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneesked 2003; 147(28): 1370–2

103.

Ilett KF, Kristensen JH, Hackett LP, Paech M, Kohan R, Rampono J. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants; Br J Clin Pharmacol 2002; 53: 17–22PubMedCrossRef

104.

Ilett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45(5): 459–62PubMedCrossRef

105.

Hendrick V, Altshuler L, Wertheimer A, et al. Venlafaxine and breast-feeding [letter]. Am J Psychiatry 2001; 158: 12CrossRef

106.

Data on file 1. Investigator’s brochure. Bracco SpA, 2000

107.

Gentile S, de Bartolomeis A, Muscettola G. Farmaci psicotropi di II generazione: possibilità e limiti di utilizzo in gravidanza ed allattamento. Giorn Ital Psicopat 2000; 6(1): 62–78

108.

Einarson A, Koren G. New antidepressants in pregnancy. Can Fam Physician 2004; 50(2): 227–9PubMed

109.

Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59(10): 767–73PubMedCrossRef

110.

Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother 1993; 27(4): 431–3PubMed

111.

Baab SW, Peindl KS, Piontek CM, et al. Serum bupropion levels in two breastfeeding mother-infant pairs. J Clin Psychiatry 2002; 63(10): 910–1PubMedCrossRef

112.

Haas JS, Kaplan CP, Barenboim D, et al. Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control 2004; 13(1): 52–6PubMedCrossRef

113.

Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of possible infant seizure [letter]. J Clin Psychiatry, 2004; 65(6): 881–2PubMedCrossRef

114.

Cohen L, Heller V, Rosembaum J. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989; 30: 25–33PubMedCrossRef

115.

Wrate RM, Rooney AC, Thomas PF, et al. Postnatal depression and child development. Br J Psychiatry 1985; 146: 622–7PubMedCrossRef

116.

Whiffen VE, Gotlib IH. Infants of postpartum depressed mothers: temperament and cognitive status. J Abnorm Psychol 1989; 98: 274–9PubMedCrossRef

117.

Wen W, Walker M. The use of selective serotonin reuptake inhibitors in pregnancy. Obstet Gynaecol Can 2004; 26(9): 819–22

118.

Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997 Mar 29; 314(7085): 932–6PubMedCrossRef

119.

Segre LS, Stuart S, O’Hara MW. Interpersonal psychotherapy for antenatal and postpartum depression. Primary Psychiatry 2004; (3): 52–6

120.

Misri S, Reebye P, Corral M, et al. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry, 2004; 65(9): 1236–41PubMedCrossRef

121.

Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45: 440–50

122.

Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry, 2004; 3(1): 2PubMedCrossRef

123.

Gupta S, Masand PS, Rangwani S. Selective reuptake inhibitors in pregnancy and lactation. Obstet Gynecol Surv, 1998; 53(12): 733–6PubMedCrossRef

124.

Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142(4): 402–8PubMedCrossRef

125.

Zeskind PS, Stephen LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Obstet Gynaecol Surv 2004; 59(8): 564–6CrossRef

126.

Morrison JL, Riggs KW, Chien C, et al. Chronic maternal fluoxetine infusion in pregnant sheep: effects on the maternal and fetal hypothalamic-pituitary-adrenal axes. Pediatr Res 2004; 56(1): 40–6PubMedCrossRef

127.

Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158(4): 312–6PubMedCrossRef

128.

Oberlander TF, Misri S, Colleen E, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65(2): 230–7PubMedCrossRef

129.

Gentile S. SSRIs in pregnancy and lactation with emphasis on neurodevelopmental outcome. CNS Drugs. In press

130.

Weissman AM, Lewy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating women, breast milk, and nursing infants. Am J Psychiatry 2004; 161(6): 1066–78PubMedCrossRef

131.

Nurnberg HG. Breast feeding and psychotropic agents. Am J Psychiatry, 1981; 138: 120–1PubMed

132.

de Vries TW, de Jong-van de Berg LTW, Hadders-Algra M. Paroxetine during lactation: is it really safe for the infant? [letter]. Acta Paediatr, 2004; 93: 1406–7PubMedCrossRef

133.

Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157–71PubMedCrossRef

134.

Ward RK, Zamorski MA. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 2002; 66(4): 629–36PubMed

135.

Nonacs R, Cohen LS. Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 2003; 26(3): 547–62PubMedCrossRef

136.

Baum LA, Misri S. Selective serotonin reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 1996; 4(3): 117–25PubMedCrossRef

137.

Falterman LG, Richardson DJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980; 97: 300–10

138.

Shearer WT, Schreiner RL, Marschall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972; 81: 221–4

139.

Cohen LS, Altshuler LL, Stowe ZN, et al. Reintroduction of antidepressant therapy across pregnancy in women who previously discontinued treatment: a preliminary retrospective study. Psychother Psychosom, 2004; 73(4): 255–8PubMedCrossRef

140.

Hosletter A, Stowe ZN, Strader Jr JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11(2): 51–7CrossRef

141.

Nulman I, Gargaun S, Koren G. Suboptimal pharmacotherapy for depression in pregnancy [abstract]. Clin Pharmacol Ther 2003; 73(2): 28CrossRef

142.

Marcus SM, Flynn HA, Blow FC, et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Women’s Health (Larchmt) 2003; 12(4): 373–80CrossRef

143.

Koren G. Discontinuation syndrome following late pregnancy exposure to antidepressants. Arch Pediatr Adolesc Med 2004; 158(4): 307–8PubMedCrossRef

144.

Cohen LS, Nonacs R, Viguera AC, et al. Diagnosis and treatment of depression during pregnancy. CNS Spectr 2004; 9(3): 209–16PubMed

Titel: The Safety of Newer Antidepressants in Pregnancy and Breastfeeding
verfasst von: Dr Salvatore Gentile
Publikationsdatum: 01.02.2005
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 2/2005
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200528020-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2005

Drugs, QT Interval Prolongation and ICH E14

Benefit-Risk Assessment of Sirolimus in Renal Transplantation

Interstitial Lung Disease in Lung Cancer

Immunotoxicology

Thiomersal in Vaccines